Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations
Open Access
- 11 October 2024
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (4) , 653-661.e3
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Public Health and the Environment
This publication has 17 references indexed in Scilit:
- Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT‐based CRC screening programInternational Journal of Cancer, 2022
- Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the NetherlandsEuropean Journal of Cancer, 2022
- A scoping review of risk-stratified bowel screening: current evidence, future directionsCancer Causes & Control, 2022
- Risk‐stratified strategies in population screening for colorectal cancerInternational Journal of Cancer, 2021
- Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based studyThe Lancet Oncology, 2021
- Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening programEuropean Journal of Cancer, 2019
- The IARC Perspective on Colorectal Cancer ScreeningNew England Journal of Medicine, 2018
- Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction modelBritish Journal of Cancer, 2017
- Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off LevelsGastroenterology, 2017
- Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening ProgramGastroenterology, 2014